DE59913264D1 - Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung - Google Patents

Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung

Info

Publication number
DE59913264D1
DE59913264D1 DE59913264T DE59913264T DE59913264D1 DE 59913264 D1 DE59913264 D1 DE 59913264D1 DE 59913264 T DE59913264 T DE 59913264T DE 59913264 T DE59913264 T DE 59913264T DE 59913264 D1 DE59913264 D1 DE 59913264D1
Authority
DE
Germany
Prior art keywords
des
immundefizienzvirus
felinen
mice
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE59913264T
Other languages
English (en)
Inventor
Rolf-M Fluegel
Martin Loechelt
Robert Flower
Ingrid Winkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to DE59913264T priority Critical patent/DE59913264D1/de
Application granted granted Critical
Publication of DE59913264D1 publication Critical patent/DE59913264D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE59913264T 1998-12-17 1999-12-17 Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung Expired - Fee Related DE59913264D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE59913264T DE59913264D1 (de) 1998-12-17 1999-12-17 Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19858441A DE19858441C2 (de) 1998-12-17 1998-12-17 FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung
DE59913264T DE59913264D1 (de) 1998-12-17 1999-12-17 Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung
PCT/DE1999/004052 WO2000036130A1 (de) 1998-12-17 1999-12-17 Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung

Publications (1)

Publication Number Publication Date
DE59913264D1 true DE59913264D1 (de) 2006-05-11

Family

ID=7891539

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19858441A Expired - Fee Related DE19858441C2 (de) 1998-12-17 1998-12-17 FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung
DE59913264T Expired - Fee Related DE59913264D1 (de) 1998-12-17 1999-12-17 Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19858441A Expired - Fee Related DE19858441C2 (de) 1998-12-17 1998-12-17 FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung

Country Status (5)

Country Link
EP (1) EP1149171B1 (de)
AT (1) ATE321144T1 (de)
AU (1) AU3031800A (de)
DE (2) DE19858441C2 (de)
WO (1) WO2000036130A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002153275A (ja) * 2000-11-17 2002-05-28 Katakura Industries Co Ltd スプーマウイルスプラスミドおよびその利用
US10378026B2 (en) * 2013-09-02 2019-08-13 Cellectis RNA based method to obtain stably integrated retroviral vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318387A1 (de) * 1993-06-03 1994-12-08 Bayer Ag Rekombinante Foamy Virus Vektoren für medizinische und diagnostische Anwendungen sowie Verfahren zur Herstellung von rekombinanten Foamy Virus Vektoren
US5882912A (en) * 1997-02-12 1999-03-16 Center For Disease Control And Prevention Retrovirus isolated from humans

Also Published As

Publication number Publication date
AU3031800A (en) 2000-07-03
WO2000036130A1 (de) 2000-06-22
EP1149171B1 (de) 2006-03-22
ATE321144T1 (de) 2006-04-15
DE19858441A1 (de) 2000-06-21
DE19858441C2 (de) 2001-02-15
EP1149171A1 (de) 2001-10-31

Similar Documents

Publication Publication Date Title
Yellow Bird What We Want to Be Called: Indigenous Peoples' Perspectives on Racial and Ethnic Identity Labels.
NO954217L (no) Guanosinrike antivirus-oligonukleotider
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
DK0597960T3 (da) Behandling af cellepopulationer
ATE238434T1 (de) Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
ATE189264T1 (de) Chimärisches oligonukleotid und dessen verwendung zur herstellung von nukleinsäure-transkripten
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
DE59913264D1 (de) Foamy-virus-vektoren zur expression von fremdgenen in säugern und deren verwendung
ES2148164T3 (es) Cepa atenuada de vacuna del virus del sarampion, que contiene una secuencia nucleotidica especifica y procedimiento para su identificacion.
EP1341909B8 (de) Eine methode zur in vitro molekularen evolution der proteinfunktion
DE69101074T2 (de) Niobtrisulfid-Katalysator zur Wasserstoffbehandlung von Kohlenwasserstoffeinsätzen und damit durchgeführtes Wasserstoffbehandlungsverfahren.
WO2002064835A3 (en) Methods for nucleic acid fingerprint analysis
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
Franco The gender wars
Leaman et al. Probe 15: Productivity: the killer variables
Kaczorowski Mattachine Society
Valitov et al. Superplasticity of nickel-based alloys with submicrocrystalline structure
Willmington Question 62-How has the nation Israel viewed the Scriptures?
ZA945417B (en) Method of inhibiting cellular entry of human immunodeficiency viruses NHIV) in HIV seropositive humans.
ZA945418B (en) Method of inhibiting the replication of human immunodeficiency viruses (HIV) in HIV seropositive humans.
Reiter L'île haute by Valentine Goby
James 1995 outlook: research strategy
Dougherty Breaking the silence
Jewsbury R. Melson." Origins of the Armenian Genocide & the Holocaust"(Book Review)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee